Furthermore, the review by Yu et al did not deal with some relevant clinical questions concerning the introduction of HE4, such as its effectiveness in post-menopausal women and in early-stage OC.
The evaluation of diagnostic performance of the combined measurements of HE4 and CA-125 was not considered, although this was the original intended application of the marker.